Literature DB >> 17415213

Establishment of an in vivo meningioma model with human telomerase reverse transcriptase.

Theresa G Cargioli1, Hasan C Ugur, Naren Ramakrishna, Jennifer Chan, Peter M Black, Rona S Carroll.   

Abstract

OBJECTIVE: The lack of meningioma models has hindered research on the pathogenesis and treatment of this commonly diagnosed primary brain tumor. Animal models of meningioma have been difficult to develop, especially those derived from Grade I tumors, which display very slow growth rates, senesce at early passages, and infrequently survive as explants in vivo. In this study, the authors report the establishment of two benign immortalized meningioma cell lines, Me10T and Me3TSC, that can serve as useful models of human meningioma.
METHODS: Tissue specimens obtained at the time of surgery were cultured in vitro and transduced with human telomerase reverse transcriptase/SV40 large T antigen to establish long-term cell lines. The telomeric activity, growth kinetics, immunophenotype, and karyotyping of the cell lines were investigated. The growth inhibitory effects of the antitumor therapies, hydroxyurea and sodium butyrate, on these cell lines were determined. In addition, immortalized cell lines were implanted subdurally into mice to confirm their ability to form tumors.
RESULTS: Two immortalized benign meningioma cell lines, Me10T and Me3TSC, transduced with catalytic subunit human telomerase reverse transcriptase alone or human telomerase reverse transcriptase and SV40 large T antigen, were established. The meningeal phenotype of the established cell cultures and orthotopic xenografts was confirmed by immunostaining. After subdural injection into athymic nude mice, both cell lines formed identifiable tumors with histological features and immunostaining patterns of human meningioma.
CONCLUSION: The Me3TSC and Me10T cell lines can serve as useful model systems for biological studies and the evaluation of novel therapies on meningioma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17415213     DOI: 10.1227/01.NEU.0000255397.00410.8F

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  9 in total

1.  Novel cell lines established from pediatric brain tumors.

Authors:  Jingying Xu; Anat Erdreich-Epstein; Ignacio Gonzalez-Gomez; Elizabeth Y Melendez; Goar Smbatyan; Rex A Moats; Michael Rosol; Jaclyn A Biegel; C Patrick Reynolds
Journal:  J Neurooncol       Date:  2011-11-27       Impact factor: 4.130

Review 2.  Meningioma mouse models.

Authors:  Michel Kalamarides; Matthieu Peyre; Marco Giovannini
Journal:  J Neurooncol       Date:  2010-08-24       Impact factor: 4.130

Review 3.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

4.  Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma.

Authors:  Hong Wei Yang; Tae-Min Kim; Sydney S Song; Nihal Shrinath; Richard Park; Michel Kalamarides; Peter J Park; Peter M Black; Rona S Carroll; Mark D Johnson
Journal:  Neoplasia       Date:  2012-01       Impact factor: 5.715

5.  Characterization and comparison of genomic profiles between primary cancer cell lines and parent atypical meningioma tumors.

Authors:  Eunhye Kim; Mirae Kim; Kyungha So; Young Seok Park; Chang Gok Woo; Sang-Hwan Hyun
Journal:  Cancer Cell Int       Date:  2020-07-28       Impact factor: 5.722

Review 6.  Modeling Brain Tumors: A Perspective Overview of in vivo and Organoid Models.

Authors:  Francesco Antonica; Giuseppe Aiello; Alessia Soldano; Luana Abballe; Evelina Miele; Luca Tiberi
Journal:  Front Mol Neurosci       Date:  2022-05-30       Impact factor: 6.261

7.  Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Authors:  Sarah S Burns; Elena M Akhmametyeva; Janet L Oblinger; Matthew L Bush; Jie Huang; Volker Senner; Ching-Shih Chen; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

8.  Development of patient-derived xenograft models from a spontaneously immortal low-grade meningioma cell line, KCI-MENG1.

Authors:  Sharon K Michelhaugh; Anthony R Guastella; Kaushik Varadarajan; Neil V Klinger; Prahlad Parajuli; Aamir Ahmad; Seema Sethi; Amro Aboukameel; Sam Kiousis; Ian M Zitron; Salah A Ebrahim; Lisa A Polin; Fazlul H Sarkar; Aliccia Bollig-Fischer; Sandeep Mittal
Journal:  J Transl Med       Date:  2015-07-15       Impact factor: 5.531

9.  SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery.

Authors:  B M Dijkstra; A Motekallemi; W F A den Dunnen; J R Jeltema; G M van Dam; F A E Kruyt; R J M Groen
Journal:  Acta Neurochir (Wien)       Date:  2018-06-01       Impact factor: 2.216

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.